Melissa Dillmon, MD
Hematology & Oncology · Rome, GANPI 1790845071
Payments from drug & device makers
Across 101 payments — averaging $104.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3K
- Beigene USA, Inc.$2K
- Seagen Inc.$2K
- Mckesson Specialty Care Distribution, LLC$1K
- AstraZeneca$456
- Johnson & Johnson$279
- plus $2K from 28 others
What the payments were for
- Consulting fees$4,43042%
- Speaking & faculty fees$2,84927%
- Food & beverage$2,85027%
- Education$4734%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 17 | $2,733 |
| Beigene USA, Inc. | 2 | $2,074 |
| Seagen Inc. | 10 | $1,881 |
| Mckesson Specialty Care Distribution, LLC | 3 | $1,044 |
| AstraZeneca | 8 | $456 |
| Johnson & Johnson | 4 | $279 |
| Sanofi | 2 | $223 |
| Taiho Oncology, Inc. | 4 | $169 |
| Foundation Medicine, Inc. | 2 | $169 |
| Puma Biotechnology, Inc. | 4 | $169 |
| Novartis | 7 | $150 |
| Daiichi Sankyo Inc. | 1 | $125 |
| Mirati Therapeutics, Inc. | 1 | $125 |
| Incyte Corporation | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $124 |
| Comsort, Inc | 1 | $100 |
| Exelixis Inc. | 1 | $85 |
| Astellas Pharma US Inc | 4 | $80 |
| Gilead | 4 | $73 |
| Amgen | 4 | $69 |
| Genentech USA, Inc. | 3 | $52 |
| Eisai Inc. | 3 | $45 |
| US Oncology Corporate, Inc. | 2 | $39 |
| AbbVie | 1 | $29 |
| Agios Pharmaceuticals, Inc. | 2 | $29 |
| Sobi, Inc | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Stemline Therapeutics Inc. | 1 | $19 |
| Karyopharm Therapeutics Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Intuitive Surgical | 1 | $16 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $13 |
| Array Biopharma Inc | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRUKINSA$2,074
- TUKYSA$1,499
- LYNPARZA$252
- CAPRELSA$200
- FOUNDATIONONE$149
- FOUNDATIONONE HEME$149
- FOUNDATIONFOCUS$149
- FOUNDATIONONE CDX$149
- IMFINZI$130
- Enhertu$125
- RYBREVANT$125
- PADCEV$125
- TECVAYLI$125
- KRAZATI$125
- MONJUVI$125
- NINLARO$124
- INQOVI$124
- Nerlynx$123
- KEYTRUDA$100
How this compares
$10,601 in reported general payments places this provider in the 55th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 81 | $1,363,165 |
| ImbruvicaIbrutinib | 63 | $859,528 |
| XtandiEnzalutamide | 37 | $506,402 |
| IbrancePalbociclib | 31 | $489,254 |
| VerzenioAbemaciclib | 32 | $485,117 |
| ErleadaApalutamide | 29 | $422,753 |
| PomalystPomalidomide | 19 | $407,555 |
| CalquenceAcalabrutinib Maleate | 21 | $311,074 |
| TagrissoOsimertinib Mesylate | 16 | $267,515 |
| BraftoviEncorafenib | 14 | $211,130 |
| TukysaTucatinib | 13 | $199,848 |
| KisqaliRibociclib Succinate | 12 | $199,491 |
| Lenalidomide | 12 | $190,298 |
| VenclextaVenetoclax | 12 | $169,602 |
| NinlaroIxazomib Citrate | 13 | $151,625 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $13 | $859,52863 claims |
| AstraZenecaCalquence, Tagrisso, Lynparza | $456 | $707,75252 claims |
| Astellas Pharma US IncXtandi | $80 | $506,40237 claims |
| PfizerIbrance | $2,733 | $489,25431 claims |
| Johnson & JohnsonErleada, Xarelto | $279 | $439,99356 claims |
| Array Biopharma IncBraftovi | $6 | $211,13014 claims |
| Seagen Inc.Tukysa | $1,881 | $199,84813 claims |
| NovartisKisqali | $150 | $199,49112 claims |
| AbbVieVenclexta | $29 | $169,60212 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $124 | $151,62513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Rome
- Mehmet BilenAtlanta$21.7M
- Steven McCuneMarietta$19.5M
- Ajay NookaAtlanta$19.3M
- Olatunji AleseAtlanta$15.5M
- Jonathon CohenAtlanta$8.7M
- Ticiana LealAtlanta$6.1M
- Amelia ZelnakCumming$4.4M
- Conor SteuerAtlanta$4.4M
- Anthony HunterAtlanta$4.3M
- Robert BrownAtlanta$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.